CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis

Journal of Leukocyte Biology

Volumn 94, Issue 5, 2013, Pages 1079-1089

  Kramer, Jill M ^a,b,c,d   Klimatcheva, Ekaterina ^e   Rothstein, Thomas L ^a,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Division of Oral and Maxillofacial Pathology   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e VACCINEX INC   (United States)

Author keywords

B cell; CXCR5; Saliva; Sialadenitis

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CXCL13 CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOTHESIS; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALIVA; SALIVARY GLAND; SERUM; SJOEGREN SYNDROME; XEROSTOMIA;

B-CELL; CXCR5; SALIVA; SIALADENITIS;

ANIMALS; CHEMOKINE CXCL13; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CXCR5; SALIVARY GLANDS; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 84887014478     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0113036     Document Type: Article

References (62)

1. Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Thean-der, E., Gottenberg, J. E., Bootsma, H., Mariette, X., Vitali, C., Force, Eular Sjögren's Task Force. (2010) EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann. Rheum. Dis. 69, 1103-1109.
2. García-Carrasco, M., Sisó, A., Ramos-Casals, M., Rosas, J., de la Red, G., Gil, V., Lasterra, S., Cervera, R., Font, J., Ingelmo, M. (2002) Ray-naud's phenomenon in primary Sjögren's syndrom: prevalence and clinical characteristics in a series of 320 patients. J. Rheumatol. 29, 726-730.
3. Ekström Smedby, K., Vajdic, C. M., Falster, M., Engels, E. A., Martínez-Maza, O., Turner, J., Hjalgrim, H., Vineis, P., Seniori Costantini, A., Bracci, P. M., Holly, E. A., Willett, E., Spinelli, J. J., La Vecchia, C., Zheng, T., Becker, N., De Sanjosé, S., Chiu, B. C., Dal Maso, L., Cocco, P., Maynadié, M., Foretova, L., Staines, A., Brennan, P., Davis, S., Sever-son, R., Cerhan, J. R., Breen, E. C., Birmann, B., Grulich, A. E., Cozen, W. (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029-4038.
4. Fox, R. I. (2005) Sjögren's syndrome. Lancet 366, 321-331.
5. Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., Pillemer, S. R., Talal, N., Weisman, M. H. (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61, 554-558.
6. Shiboski, S. C., Shiboski, C. H., Criswell, L., Baer, A., Challacombe, S., Lanfranchi, H., Schiødt, M., Umehara, H., Vivino, F., Zhao, Y., Dong, Y., Greenspan, D., Heidenreich, A. M., Helin, P., Kirkham, B., Kitagawa, K., Larkin, G., Li, M., Lietman, T., Lindegaard, J., McNamara, N., Sack, K., Shirlaw, P., Sugai, S., Vollenweider, C., Whitcher, J., Wu, A., Zhang, S., Zhang, W., Greenspan, J., Daniels, T., Groups, Sjögren's Syndrome International Collaborate Clinical Alliance Research Groups. (2012) American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. 64, 475-487.
7. Segal, B., Bowman, S. J., Fox, P. C., Vivino, F. B., Murukutla, N., Brod-scholl, J., Ogale, S., McLean, L. (2009) Primary Sjögren's syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual. Life. Outcomes 7, 46.
8. Zhong, X., Gao, W., Degauque, N., Bai, C., Lu, Y., Kenny, J., Oukka, M., Strom, T. B., Rothstein, T. L. (2007) Reciprocal generation of Th1/ Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37, 2400-2404.
9. Youinou, P. (2008) Sjögren's syndrome: a quintessential B cell-induced autoimmune disease. Joint Bone Spine 75, 1-2.
10. Hansen, A., Gosemann, M., Pruss, A., Reiter, K, Ruzickova, S., Lipsky, P. E., Dorner, T. (2004) Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum. 50, 1897-1908.
11. Bohnhorst, J. O., Bjorgan, M. B., Thoen, J. E., Natvig, J. B., Thompson, K. M. (2001) Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J. Immunol. 167, 3610-3618.
12. Binard, A, Le Pottier, L., Devauchelle-Pensec, V., Saraux, A, Youinou, P., Pers, J. O. (2008) Is the blood B-cell subset profile diagnostic for Sjögren's syndrome? Ann. Rheum. Dis.
13. Youinou, P., Mackenzie, L., le Masson, G., Papadopoulos, N. M., Jouquan, J., Pennec, Y L., Angelidis, P., Katsikis, P., Moutsopoulos, H. M., Lydyard, P. M. (1988) CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J. Autoimmun. 1, 185-194.
14. Zeher, M., Surányi, P., Nagy, G., Szegedi, G. (1990) B cells expressing CD5 in minor labial salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 33, 453.
15. Rotondi, M., Chiovato, L., Romagnani, S., Serio, M., Romagnani, P. (2007) Role of chemokines in endocrine autoimmune diseases. Endocr. Rev. 28, 492-520.
16. Hansen, A, Reiter, K, Ziprian, T., Jacobi, A, Hoffmann, A, Gosemann, M., Scholze, J., Lipsky, P. E., Dorner, T. (2005) Dysregulation of chemo-kine receptor expression and function by B cells of patients with primary Sjögren's syndrome. Arthritis Rheum. 52, 2109-2119.
17. Manzo, A., Vitolo, B., Humby, F., Caporali, R, Jarrossay, D., Dell'accio, F., Ciardelli, L., Uguccioni, M., Montecucco, C, Pitzalis, C. (2008) Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 58, 3377-3387.
18. Gunn, M. D., Ngo, V. N., Ansel, K. M., Ekland, E. H., Cyster, J. G., Williams, L. T. (1998) A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391, 799-803.
19. Cyster, J. G., Ansel, K. M., Reif, K, Ekland, E. H., Hyman, P. L., Tang, H. L., Luther, S. A., Ngo, V. N. (2000) Follicular stromal cells and lymphocyte homing to follicles. Immunol. Rev. 176, 181-193.
20. Forster, R, Mattis, A. E., Kremmer, E., Wolf, E., Brem, G., Lipp, M. (1996) A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037-1047.
21. Ansel, K. M., Harris, R B., Cyster, J. G. (2002) CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16, 67-76.
22. Luther, S. A, Lopez, T., Bai, W., Hanahan, D., Cyster, J. G. (2000) BLC expression in pancreatic islets causes B cell recruitment and lympho-toxin-dependent lymphoid neogenesis. Immunity 12, 471-481.
23. Sellebjerg, F., Bornsen, L., Khademi, M., Krakauer, M., Olsson, T., Fred-eriksen, J. L., Sorensen, P. S. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73, 2003-2010.
24. Rioja, I., Hughes, F. J., Sharp, C. H., Warnock, L. C, Montgomery, D. S., Akil, M., Wilson, A. G., Binks, M. H., Dickson, M. C. (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor Arthritis Rheum. 58, 2257-2267.
25. Lee, H. T., Shiao, Y M., Wu, T. H., Chen, W. S., Hsu, Y H., Tsai, S. F., Tsai, C. Y Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J. Rheumatol. 37, 45-52.
26. Nauntofte, B., Dissing, S. (1987) Stimulation-induced changes in cy-tosolic calcium in rat parotid acini. Am. J. Physiol. 253, G290-G297.
27. Zhong, X., Tumang, J. R, Gao, W., Bai, C, Rothstein, T. L. (2007) PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur. J. Immunol. 37, 2405-2410.
28. Lee, B. P., Chen, W., Shi, H., Der, S. D., Förster, R., Zhang, L. (2006) CXCR5/CXCL13 interaction is important for double-negative regulatory T cell homing to cardiac allografts. J. Immunol. 176, 5276-5283.
29. Schiffer, L., Bethunaickan, R, Ramanujam, M., Huang, W., Schiffer, M., Tao, H., Madaio, M. P., Madaio, M. M., Bottinger, E. P., Davidson, A. (2008) Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J. Immunol. 180, 1938-1947.
30. Zheng, B., Ozen, Z., Zhang, X., De Silva, S., Marinova, E., Guo, L., Wansley, D., Huston, D. P., West, M. R, Han, S. (2005) CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum. 52, 620-626.
31. Delaleu, N., Nguyen, C. Q., Peck, A. B., Jonsson, R. (2011) Sjögren's syndrome: studying the disease in mice. Arthritis Res. Ther. 13, 217.
32. Forster, R. (2000) CXCR5. In Cytokine Reference, Vol. 2. (J. Oppenheim, J. Feldmann, M. Durum, S. K. Hirano, T. Vilcek, and J. Nicos, eds), N. A. Academic, New York 2019-2024.
33. Sreebny, L. M. (2000) Saliva in health and disease: an appraisal and update. Int. Dent. J. 50, 140-161.
34. Zhou, D., Chen, Y. T., Chen, F., Gallup, M., Vijmasi, T., Bahrami, A. F., Noble, L. B., van Rooijen, N., McNamara, N. A. (2012) Critical involvement of macrophage infiltration in the development of Sjögren's Syndrome-associated dry eye. Am. J. Pathol. 181, 753-760.
35. Moreth, K., Brodbeck, R., Babelova, A., Gretz, N., Spieker, T., Zeng-Brouwers, J., Pfeilschifter, J., Young, M. F., Schaefer, R. M., Schaefer, L. (2010) The proteoglycan biglycan regulates expression of the B cell che-moattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest. 120, 4251-4272.
36. Sica, A., Mantovani, A. (2012) Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795.
37. Tzioufas, A. G., Kapsogeorgou, E. K., Moutsopoulos, H. M. (2012) Pathogenesis of Sjögren's syndrome: what we know and what we should learn. J. Autoimmun. 39, 4-8.
38. Ngo, V. N., Korner, H., Gunn, M. D., Schmidt, K. N., Riminton, D. S., Cooper, M. D., Browning, J. L., Sedgwick, J. D., Cyster, J. G. (1999) Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189, 403-412.
39. Fava, R. A., Kennedy, S. M., Wood, S. G., Bolstad, A. I., Bienkowska, J., Papandile, A., Mavragani, C. P., Gatumu, M., Skarstein, K., Kelly, J. A., Browning, J. L. (2011) Lymphotoxin-beta Receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. Arthritis Res. Ther. 13, R182.
40. Gatumu, M. K., Skarstein, K., Papandile, A., Browning, J. L., Fava, R. A., Bolstad, A. I. (2009) Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 11, R24.
41. Henry, R. A., Kendall, P. L. (2010) CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. J. Immunol. 185, 1460-1465.
42. Aust, G., Sittig, D., Becherer, L., Anderegg, U., Schutz, A., Lamesch, P., Schmucking, E. (2004) The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur. J. Endocrinol. 150, 225-234.
43. Bagaeva, L. V., Rao, P., Powers, J. M., Segal, B. M. (2006) CXC chemo-kine ligand 13 plays a role in experimental autoimmune encephalomy-elitis. J. Immunol. 176, 7676-7685.
44. Meraouna, A., Cizeron-Clairac, G., Panse, R. L., Bismuth, J., Truf-fault, F., Tallaksen, C., Berrih-Aknin, S. (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108, 432-440.
45. Sato, T., Ishikawa, S., Akadegawa, K., Ito, T., Yurino, H., Kitabatake, M., Yoneyama, H., Matsushima, K. (2004) Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 34, 3346-3358.
46. Shi, K., Hayashida, K., Kaneko, M., Hashimoto, J., Tomita, T., Lipsky, P. E., Yoshikawa, H., Ochi, T. (2001) Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ecto-pic lymphoid follicles within the synovium of chronic arthritis patients. J. Immunol. 166, 650-655.
47. Baldini, C., Giusti, L., Ciregia, F., Da Valle, Y., Giacomelli, C., Donadio, E., Sernissi, F., Bazzichi, L., Giannaccini, G., Bombardieri, S., Lucac-chini, A. (2011) Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res. Ther. 13, R194.
48. Ambatipudi, K. S., Swatkoski, S., Moresco, J. J., Tu, P. G., Coca, A., Ano-lik, J. H., Gucek, M., Sanz, I., Yates, J. R., Melvin, J. E. (2012) Quantitative proteomics of parotid saliva in primary Sjögren's syndrome. Proteom-ics 12, 3113-3120.
49. Ching, K. H., Burbelo, P. D., Gonzalez-Begne, M., Roberts, M. E., Coca, A., Sanz, I., Iadarola, M. J. (2011) Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjögren's Syndrome. J. Dent. Res. 90, 445-449.
50. Brkic, Z., Maria, N. I., van Helden-Meeuwsen, C. G., van de Merwe, J. P., van Daele, P. L., Dalm, V. A., Wildenberg, M. E., Beumer, W., Drexhage, H. A., Versnel, M. A. (2012) Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis.
51. Mavragani, C. P., Crow, M. K. (2010) Activation of the type I inter-feron pathway in primary Sjögren's syndrome. J. Autoimmun. 35, 225-231.
52. Gottenberg, J. E., Cagnard, N., Lucchesi, C., Letourneur, F., Mistou, S., Lazure, T., Jacques, S., Ba, N., Ittah, M., Lepajolec, C., Labetoulle, M., Ardizzone, M., Sibilia, J., Fournier, C., Chiocchia, G., Mariette, X. (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl. Acad. Sci. U. S. A. 103, 2770-2775.
53. Low, H. Z., Witte, T. (2011) Aspects of innate immunity in Sjögren's syndrome. Arthritis Res. Ther. 13, 218.
54. Segal, B. M., Nazmul-Hossain, A. N., Patel, K., Hughes, P., Moser, K. L., Rhodus, N. L. (2011) Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 111, 673-680.
55. Killedar, S. J., Killedar, S. Y., Eckenrode, S. E., McIndoe, R. A., She, J. X., Nguyen, C. Q., Peck, A. B., Cha, S. R., Cha, S. (2006) Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis. Lab. Invest. 86, 1243-1260.
56. Groom, J., Kalled, S. L., Cutler, A. H., Olson, C., Woodcock, S. A., Schneider, P., Tschopp, J., Cachero, T. G., Batten, M., Wheway, J., Mauri, D., Cavill, D., Gordon, T. P., Mackay, C. R., Mackay, F. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109, 59-68.
57. Szodoray, P., Jellestad, S., Teague, M. O., Jonsson, R. (2003) Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome. Lab. Invest. 83, 357-365.
58. Badr, G., Borhis, G., Lefevre, E. A., Chaoul, N., Deshayes, F., Dessirier, V., Lapree, G., Tsapis, A., Richard, Y. (2008) BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 111, 2744-2754.
59. Daridon, C., Devauchelle, V., Hutin, P., Le Berre, R., Martins-Carvalho, C., Bendaoud, B., Dueymes, M., Saraux, A., Youinou, P., Pers, J. O. (2007) Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 56, 1134-1144.
60. Hansen, A., Lipsky, P. E., Dörner, T. (2007) B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res. Ther. 9, 218.
61. Coca, A., and Sanz, I. (2012) Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjögren's syndrome. Curr. Opin. Rheu-matol. 24, 451-456.
62. Daniels, T. E., Cox, D., Shiboski, C. H., Schiødt, M., Wu, A., Lanfranchi, H., Umehara, H., Zhao, Y., Challacombe, S., Lam, M. Y., De Souza, Y., Schiødt, J., Holm, H., Bisio, P. A., Gandolfo, M. S., Sawaki, T., Li, M., Zhang, W., Varghese-Jacob, B., Ibsen, P., Keszler, A., Kurose, N., No-jima, T., Odell, E., Criswell, L. A., Jordan, R., Greenspan, J. S., Groups, S., Sjögren's International Collaborative Clinical Alliance Research Groups. (2011) Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. Arthritis Rheum. 63, 2021-2030.